your badges 52W Range $1–$7 44% of range Analyst Rating BUY 9 analysts Price Target $9 +151% upside P/E -5.0 ROE -57.7% Net Profit Margin -269.7%

PRLD Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $3.67
P/E (TTM) -5.0
EPS (TTM) $-0.73
Revenue (TTM) $22M
ROE (TTM) -57.7%
52W Range $1–$7

PRLD Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$12M
2024-12-31 → 2025-12-31
EPS$-1.29
2021-12-31 → 2025-12-31
Free Cash Flow$-56M
2020-12-31 → 2025-12-31
Net margin-269.7%
2024-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend PRLD 5Y avg Peer Median Verdict
P/E (TTM) -5.05Y avg ≈-2.5 ≈-2.5 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -74.3%
Next Report Nov 10, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 19, 2026 $-0.14 $-0.20 30.2%
March 31, 2026 May 12, 2026 $-0.13 $-0.25 48.7%
Dec. 31, 2025 $-0.20 $-0.03 -575.7%
Sept. 30, 2025 $-0.26 $-0.37 30.2%
June 30, 2025 $-0.41 $-0.45 8.5%
March 31, 2025 $-0.42 $-0.48 12.1%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 13
Metric Trend 20252024
Revenue $12M$7M
R&D Expense $94M$118M
SG&A Expense $22M$29M
Operating Expenses $117M$147M
Operating Income $-105M$-140M
Other Non-op $5M$13M
Income Tax $0$0
Net Income $-99M$-127M
EPS (Basic) $-1.29$-1.68
EPS (Diluted) $-1.29$-1.68
Shares (Basic) 76,956,19475,805,840
Shares (Diluted) 76,956,19475,805,840
EBITDA $-103M$-138M
Balance Sheet 18
Metric Trend 20252024
Cash & Equivalents $35M$12M
Short-term Investments $68M$121M
Prepaid Expense $2M$2M
Current Assets $106M$136M
PP&E (Net) $5M$7M
PP&E (Gross) $12M$12M
Accum. Depreciation $7M$5M
Total Assets $141M$176M
Accounts Payable $4M$8M
Accrued Liabilities $13M$15M
Current Liabilities $53M$26M
Capital Leases $15M$15M
Other Non-current Liabilities $3M$3M
Total Liabilities $73M$44M
Retained Earnings $-683M$-584M
AOCI $8.0K$35.0K
Stockholders' Equity $69M$131M
Liabilities + Equity $141M$176M
Cash Flow 11
Metric Trend 20252024
D&A $2M$2M
Stock-based Comp $12M$21M
Restructuring $1M·
Other Non-cash $30M$1M
Operating Cash Flow $-56M$-103M
CapEx $67.0K$764.0K
Investing Cash Flow $53M$90M
Financing Cash Flow $25M$-120.0K
Net Change in Cash $22M$-13M
Taxes Paid $0$0
Free Cash Flow $-56M$-104M
Profitability 5
Metric Trend 20252024
Operating Margin -861.3%-1995.9%
Net Margin -819.6%-1816.8%
EBITDA Margin -847.2%-1970.6%
ROA -62.8%-56.1%
ROE -137.7%-88.3%
Liquidity & Solvency 2
Metric Trend 20252024
Current Ratio 2.05.3
Quick Ratio 1.95.2
Efficiency 1
Metric Trend 20252024
Asset Turnover 0.10.0
Per Share 3
Metric Trend 20252024
Revenue / Share $0.16$0.09
Cash Flow / Share $-0.73$-1.36
EPS (TTM) $-1.29$-1.68
Growth Rates 1
Metric Trend 20252024
Revenue YoY 73.4%·
Valuation (TTM) 4
Metric Trend 20252024
Revenue TTM $12M$7M
Net Income TTM $-99M$-127M
P/E -2.2-0.8
Earnings Yield -44.5%-131.8%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $12M $7M · · ·
Operating Margin % -861.3% -1995.9% · · ·
Net Income $-99M $-127M $-122M $-115M $-112M
Diluted EPS $-1.29 $-1.68 $-2.02 $-2.44 $-2.43

Institutional owners (13F) 84 filers · $267.3M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 84
Value held $267.3M
New positions 39
Exited positions 11
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
39 (+25 vs prior Q) 11 (+7 vs prior Q) 26 (+6 vs prior Q) 8 (-3 vs prior Q) +19.1M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
ORBIMED ADVISORS LLC $73,151,963 13,724,571 27.36% Shares
BAKER BROS. ADVISORS LP $53,959,982 10,123,824 20.19% Shares
RA CAPITAL MANAGEMENT, L.P. $34,516,451 6,475,882 12.91% Shares
Soleus Capital Management, L.P. $18,006,755 3,378,378 6.74% Shares
Kynam Capital Management, LP $12,872,414 2,415,087 4.82% Shares
VANGUARD CAPITAL MANAGEMENT LLC $10,710,342 2,009,445 4.01% Shares
BlackRock, Inc. $9,580,681 1,797,501 3.58% Shares
SPHERA FUNDS MANAGEMENT LTD. $5,435,705 1,019,832 2.03% Shares
TWO SIGMA INVESTMENTS, LP $5,294,657 993,369 1.98% Shares
ADAR1 Capital Management, LLC $4,801,797 900,900 1.80% Shares
MILLENNIUM MANAGEMENT LLC $4,503,813 844,993 1.68% Shares
GEODE CAPITAL MANAGEMENT, LLC $4,487,860 841,862 1.68% Shares
VANGUARD GROUP INC $4,100,559 1,413,986 1.53% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $4,083,286 766,095 1.53% Shares
MORGAN STANLEY $2,685,574 503,860 1.00% Shares
STATE STREET CORP $2,285,435 428,787 0.85% Shares
UBS Group AG $1,699,188 318,797 0.64% Shares
VANGUARD FIDUCIARY TRUST CO $1,518,442 284,886 0.57% Shares
RENAISSANCE TECHNOLOGIES LLC $1,498,796 281,200 0.56% Shares
NORTHERN TRUST CORP $1,282,393 240,599 0.48% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $1,033,594 193,920 0.39% Shares
MARSHALL WACE, LLP $1,016,387 190,692 0.38% Shares
TWO SIGMA ADVISERS, LP $688,170 237,300 0.26% Shares
Connor, Clark & Lunn Investment Management Ltd. $669,480 125,606 0.25% Shares
GOLDMAN SACHS GROUP INC $644,045 120,834 0.24% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $591,630 111,000 0.22% Call option
Hillsdale Investment Management Inc. $433,862 81,400 0.16% Shares
Bank of New York Mellon Corp $363,436 68,187 0.14% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $360,425 67,622 0.13% Shares
BRIDGEWAY CAPITAL MANAGEMENT, LLC $343,785 64,500 0.13% Shares
JANE STREET GROUP, LLC $341,653 64,100 0.13% Call option
SUSQUEHANNA INTERNATIONAL GROUP, LLP $339,521 63,700 0.13% Put option
Squarepoint Ops LLC $317,348 59,540 0.12% Shares
PANAGORA ASSET MANAGEMENT INC $253,569 47,574 0.09% Shares
Mariner, LLC $241,241 45,261 0.09% Shares
Nuveen, LLC $197,333 37,023 0.07% Shares
DIMENSIONAL FUND ADVISORS LP $186,839 35,210 0.07% Shares
Invesco Ltd. $185,175 34,742 0.07% Shares
Cerity Partners LLC $175,224 32,875 0.07% Shares
State of Wyoming $175,154 32,862 0.07% Shares
CITADEL ADVISORS LLC $166,829 31,300 0.06% Put option
Graham Capital Management, L.P. $158,674 29,770 0.06% Shares
DEUTSCHE BANK AG\ $148,302 27,824 0.06% Shares
WELLS FARGO & COMPANY/MN $134,982 25,325 0.05% Shares
BANK OF AMERICA CORP /DE/ $127,254 23,875 0.05% Shares
CITADEL ADVISORS LLC $120,213 22,554 0.04% Shares
RHUMBLINE ADVISERS $117,649 22,074 0.04% Shares
JANE STREET GROUP, LLC $107,133 20,100 0.04% Put option
Vanguard Global Advisers, LLC $86,399 16,210 0.03% Shares
CITADEL ADVISORS LLC $85,813 16,100 0.03% Call option

Show all 84 institutional owners →

Activists & 5%+ owners 2 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC ×4 filings April 23, 2026 16.00% Amendment · SEC
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×6 filings April 22, 2026 15.50% Amendment Capital structure SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 17 insiders · 11 officers · 7 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Krishna Vaddi CEO Feb. 4, 2026 A 1,999,296 0 0 $0
Bryant David Lim CLO, CFO, Corp Sec. Feb. 4, 2026 A 27,400 0 0 $0
Laurent Chardonnet Chief Financial Officer March 1, 2024 A 42,165 0 0 $0
Brian Piper Chief Financial Officer Aug. 25, 2021 M 0 0 0 $0
Jane Huang President, CMO Oct. 4, 2025 M 86,917 0 0 $0
Charles Q Morris Chief Medical Officer May 1, 2026 A · 0 0 $0
Andrew Combs Chief Chemistry Officer Feb. 4, 2026 A 480,123 0 0 $0
Peggy Scherle Chief Scientific Officer Feb. 4, 2026 A 172,920 0 0 $0
Deborah Morosini EVP, Chief of Clinical Affairs Feb. 15, 2022 A 444 0 0 $0
David J Mauro Chief Medical Officer Oct. 5, 2021 M 0 0 0 $0
Christopher Pierce EVP and Chief of Business Oper Sept. 2, 2021 M 3,750 0 0 $0
Victor Sandor Director June 9, 2026 A · 0 0 $0
Katina Dorton Director June 9, 2026 A · 0 0 $0
David P Bonita Director June 9, 2026 A 1,126,126 2 0 $12,499,998
Martin Babler Director June 9, 2026 A · 0 0 $0
Paul A Friedman, M.D. Director June 9, 2026 A 500,098 0 0 $0
Mardi Dier Director June 12, 2025 A 10,000 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 13 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IWC · iShares Trust 0.03% 92,467 SH Sept. 11, 2026 Daily
OMFS · Invesco Exchange-Traded Self-Indexe… 0.03% 19,546 SH Oct. 2, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.01% 29,931 SH Aug. 19, 2026 Daily
IWO · iShares Trust 0.01% 260,735 SH Sept. 11, 2026 Daily
IWM · iShares Trust 0.00% 694,659 SH Sept. 11, 2026 Daily
RSSL · Global X Funds 0.00% 13,254 NS July 31, 2026 N-PORT
DFSU · Dimensional ETF Trust 0.00% 3,323 NS July 31, 2026 N-PORT
DFAS · Dimensional ETF Trust 0.00% 7,414 NS July 31, 2026 N-PORT
DCOR · Dimensional ETF Trust 0.00% 1,348 NS July 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.00% 458,355 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 1,513,825 SH Aug. 19, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.00% 160,484 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 3,505 SH Aug. 19, 2026 Daily

PRLD Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 9 analysts BUY
Median target $10.00 +172.5%
3 33.3% Strong Buy
5 55.6% Buy
1 11.1% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

5 analysts · 2026-10-01

Mean target $9.20 +150.7%

← Below all targets Current price $3.67
Low$6.00 Mean$9.20 High$12.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
PRLD · -2.2 73.4% -819.6% -137.7% ·
BNTC $460M -13.7 · · -25.0% ·
BBOT $1.00B -2.9 · · -146.2% ·
LRMR $317M -2.2 · · -167.4% ·
LXEO $725M -5.3 · · -51.9% ·
ABEO $290M 5.2 147.5% 1223.1% 44.1% ·
UPB $1.47B -10.2 20.4% -5026.0% -38.3% ·
VNDA $521M -2.4 8.7% -102.0% -54.2% ·
RCKT · · · · · ·

Latest News Recent headlines mentioning this company

23
Prelude Therapeutics Appoints Charles Morris As Chief Medical Officer Nasdaq · 5 months, 2 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 11, 2026